| Gene regulation and suppression of type I interferon signaling by STAT3 in diffuse large B cell lymphoma L Lu, F Zhu, M Zhang, Y Li, AC Drennan, S Kimpara, I Rumball, C Selzer, ... Proceedings of the National Academy of Sciences 115 (3), E498-E505, 2018 | 92 | 2018 |
| PRMT5 in gene regulation and hematologic malignancies F Zhu, L Rui Genes & Diseases 6 (3), 247-257, 2019 | 71 | 2019 |
| Epigenetic gene regulation by Janus kinase 1 in diffuse large B-cell lymphoma L Rui, AC Drennan, M Ceribelli, F Zhu, GW Wright, DW Huang, W Xiao, ... Proceedings of the National Academy of Sciences 113 (46), E7260-E7267, 2016 | 70 | 2016 |
| STAT3 activation and oncogenesis in lymphoma F Zhu, KB Wang, L Rui Cancers 12 (1), 19, 2019 | 69 | 2019 |
| PRMT5 is upregulated by B-cell receptor signaling and forms a positive-feedback loop with PI3K/AKT in lymphoma cells F Zhu, H Guo, PD Bates, S Zhang, H Zhang, KJ Nomie, Y Li, L Lu, ... Leukemia 33 (12), 2898-2911, 2019 | 59 | 2019 |
| A Golgi-localized pool of the mitotic checkpoint component Mad1 controls integrin secretion and cell migration J Wan, F Zhu, LM Zasadil, J Yu, L Wang, A Johnson, E Berthier, DJ Beebe, ... Current Biology 24 (22), 2687-2692, 2014 | 30 | 2014 |
| Nuclear import of JAK1 is mediated by a classical NLS and is required for survival of diffuse large B-cell lymphoma F Zhu, B Hwang, S Miyamoto, L Rui Molecular Cancer Research 15 (3), 348-357, 2017 | 18 | 2017 |
| Inhibition of the STAT3 target SGK1 sensitizes diffuse large B cell lymphoma cells to AKT inhibitors L Lu, F Zhu, Y Li, S Kimpara, NM Hoang, S Pourdashti, L Rui Blood cancer journal 9 (4), 43, 2019 | 15 | 2019 |
| A mix of S and ΔS variants of STAT3 enable survival of activated B-cell-like diffuse large B-cell lymphoma cells in culture M Zheng, KB Turton, F Zhu, Y Li, KM Grindle, DS Annis, L Lu, AC Drennan, ... Oncogenesis 5 (1), e184-e184, 2016 | 14 | 2016 |
| CXCR4 allows T cell acute lymphoblastic leukemia to escape from JAK1/2 and BCL2 inhibition through CNS infiltration KL Walker, SP Rinella, NJ Hess, DP Turicek, SA Kabakov, F Zhu, ... Leukemia & lymphoma 62 (5), 1167-1177, 2021 | 13 | 2021 |
| Hyperphosphorylation of BCL-2 family proteins underlies functional resistance to venetoclax in lymphoid malignancies SJF Chong, F Zhu, O Dashevsky, R Mizuno, JXH Lai, L Hackett, CE Ryan, ... The Journal of clinical investigation 133 (22), 2023 | 11 | 2023 |
| EGR1 addiction in diffuse large B-cell lymphoma S Kimpara, L Lu, NM Hoang, F Zhu, PD Bates, A Daenthanasanmak, ... Molecular Cancer Research 19 (8), 1258-1269, 2021 | 7 | 2021 |
| Hypomethylating agent decitabine sensitizes diffuse large B-cell lymphoma to venetoclax F Zhu, JL Crombie, W Ni, NM Hoang, S Garg, L Hackett, SJF Chong, ... Haematologica 109 (1), 186, 2024 | 6 | 2024 |
| NR4A1 inhibition synergizes with ibrutinib in killing mantle cell lymphoma cells Y Li, F Wang, L Lu, F Zhu, S Huang, K Nomie, L Zhang, DT Yang, ... Blood cancer journal 7 (12), 632, 2017 | 6 | 2017 |
| Loss-of-function of Fbxo10, encoding a post-translational regulator of BCL2 in lymphomas, has no discernible effect on BCL2 or B lymphocyte accumulation in mice E Masle-Farquhar, A Russell, Y Li, F Zhu, L Rui, R Brink, CC Goodnow Plos one 16 (4), e0237830, 2021 | 3 | 2021 |
| Dissecting Richter's syndrome in a multiplexed CRISPR-based mouse model reveals key changes in MYC, interferon and BCR signaling underlying transformation E Ten Hacken, S Yin, T Sewastianik, L Penter, N Ruthen, M Gruber, ... Blood 138, 251, 2021 | 2 | 2021 |
| Efficacy of JAK1/2 and BCL2 inhibition on human T cell acute lymphoblastic leukemia in vitro and in vivo KL Walker, SA Kabakov, F Zhu, MN Bouchlaka, SL Olson, MM Cho, ... bioRxiv, 2020 | 2 | 2020 |
| Targeting BCL2 family protein phosphorylation in venetoclax resistant lymphoid malignancies SJ Chong, F Zhu, JX Lai, L Hackett, MC Collins, S Pervaiz, JP Coppe, ... Cancer Research 82 (12_Supplement), 3959-3959, 2022 | 1 | 2022 |
| Targeting DNMT3A-mediated oxidative phosphorylation to overcome ibrutinib resistance in mantle cell lymphoma NM Hoang, Y Liu, PD Bates, AR Heaton, AF Lopez, P Liu, F Zhu, R Chen, ... Cell Reports Medicine 5 (4), 2024 | | 2024 |
| Inhibiting β-catenin in AML by targeting DDX5 WEI NI, S Garg, F Zhu, EL Weisberg, B Chowdhury, M Sattler, A Jakkani, ... Cancer Research 83 (7_Supplement), 6248-6248, 2023 | | 2023 |
